Patients with category II or III risk of coronary artery disease ( CAD ) , or those with a history of CAD ( secondary prevention ) , who had not achieved their JAS2007GL LDL-C goals during treatment with atorvastatin for at least 4 weeks were switched either to rosuvastatin 5 mg/day ( from atorvastatin 10 mg/day ) or rosuvastatin 10 mg/day ( from atorvastatin 20 mg/day ) ( n = 75 ) or continued to receive atorvastatin ( n = 77 ) .